Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Merck continues to build on its leadership in oncology by advancing a diverse portfolio of investigational candidates and exploring novel modalities with the goal of improving outcomes and helping to address significant unmet needs for patients with hematologic neoplasms and malignancies

  80% confidence

• Merck aspires to be the premier research-intensive biopharmaceutical company in the world

  80% confidence

• The data shared at ASH 2025 reflect the continued growth and evolution of Merck's promising hematology pipeline

  80% confidence

• There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful

  80% confidence

Data points we hold from this source